COMMUNIQUÉS West-GlobeNewswire

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12/02/2024
Company shares behind-the-scenes look at its GMP MDMA encapsulation and production process VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ [...]
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
12/02/2024
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 [...]
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
12/02/2024
Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and [...]
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
12/02/2024
Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events Dose dependent increases in frataxin levels were observed in [...]
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12/02/2024
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous [...]
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
12/02/2024
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal years Initial [...]
ECO Animal Health Appoints Dr. Joachim Hasenmaier as Non-Executive Director
12/02/2024
12 February 2024 ECO Animal Health Group plc (“ECO” or the “Company”) Appointment of Dr. Joachim Hasenmaier as Non-Executive Director ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health [...]
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
12/02/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions [...]
PCI Biotech: Invitation to second half interim 2023 results presentation
12/02/2024
Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The [...]
Ibogaine By David Dardashti Shares Biomedical Engineers Take on Holistic Treatment
11/02/2024
Mark Leslie Mitchelson, MD Praises Alternative Approach to Health and Wellness MIAMI, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti and Doctor Mark Leslie Mitchelson offer insights behind ibogaine [...]
Ibogaine By David Dardashti Makes Statement on Public Concerns Regarding Fentanyl Distribution
11/02/2024
Miami, Feb. 10, 2024 (GLOBE NEWSWIRE) -- In light of the rising threat of fentanyl distribution in the United States and its ties to China's massive debts, Ibogaine By David Dardashti, a leader in addiction recovery [...]
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
10/02/2024
The FDA has accepted a New Drug Application filed by Lykos Therapeutics for MDMA-assisted therapy for PTSD The application was supported by clinical trial data collected over two decades of research incubated by MAPS [...]
Vision Sensing Acquisition Corp. Announces Filing of Form 10-Q with the SEC For the Quarterly Period Ended September 30, 2023, Regaining Compliance with the Filing Requirement in Nasdaq Listing Rule 5250(c)(1)
09/02/2024
MIAMI, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that on February 7, 2024, the Company filed [...]
New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
09/02/2024
BOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation of preliminary data from The S quid T rial for the E mbolization of the M iddle [...]
PickleJar Debuts "Win Now" Technology to Simplify Contesting Programs With Strategic Partners and Reward Fans
09/02/2024
HOUSTON, TX, Feb. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PickleJar Entertainment Group, f/k/a NewRegen, Inc. (OTC:NREG) , a leading Texas-based music and entertainment software company, today announced new [...]
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
09/02/2024
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their [...]
Coloplast A/S - Allocation of Share Options
09/02/2024
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives [...]
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market
09/02/2024
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced the acquisition of all the issued and outstanding [...]
MedBright AI Announces Closing of LIFE Offering for Gross Proceeds of Approximately $1.4 Million
09/02/2024
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. ( CSE: MBAI ) ( [...]

Pages